For subscribers that have a Database Subscription, we’ve added a new table that you can now find under the SPACs tab: At-Risk Capital / Promote.
We’ve detailed each SPAC team’s at-risk capital as well as the sponsor’s promote for all SPACs by category: Searching for a Target, Announced a Transaction, and currently Filed for IPO. Now you can see just how much is at stake…
A snapshot of the current “Filed for IPO” category has been provided below, but in order to view the other two categories, you will need to be a subscriber.
For those unfamiliar with the term, the at-risk capital of the sponsors is contributed at the time of the IPO via a private placement purchase of either warrants or units. It is this capital that pays for the expenses of the offering (i.e., underwriters’ discount, legal and accounting fees, printing costs, filing fees, etc.) and is what brings the trust amount to 100% (or greater if the trust is over-funded). However, it is fully “at-risk” since if the SPAC cannot complete a business combination and liquidates, the sponsor loses the entire investment. It’s some serious “skin in the game.”
For subscribers you can find the new table HERE.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...